EFdA-TP (tetralithium)

• Description :

  EFdA-TP tetralithium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetralithium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT) . EFdA-TP tetralithium inhibits HIV-1 RT with multiple mechanisms[1].

• UNSPSC :

  12352005

• Target :

  HIV; Reverse Transcriptase

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Purity :

  96.23

• Solubility :

  H2O : ≥ 100 mg/mL

• Smiles :

  O=[P](O[P](O[P](O[Li])(O[Li])=O)(O[Li])=O)(O[Li])OC[C@]1(O[C@@](C[C@@H]1O)([H])N2C3=NC(F)=NC(N)=C3N=C2)C#C

• Molecular Formula :

  C12H11FLi4N5O12P3

• Molecular Weight :

  556.93

• References & Citations :

  [1]Eleftherios Michailidis, et al. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem. 2014 Aug 29;289 (35) :24533-48.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, protect from light, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported